Catalyst Wire Dossier Catalyst Wire Dossier

SAF312 Eye Drops

SAF312 · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SAF312 Eye Drops, covering 2024-04-18 to 2024-04-18. Get the full timeline:

Most recent: Clinical Trial Update: Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP) [Phase 2]

See pricing